Recombinant Human anti-COVID-19/SARS-CoV-2 RBD Monoclonal Antibody
-
产品编号
MAV101
-
别名
SARS-CoV-2 RBD antibody, 2019-nCoV, Coronavirus
-
规格
- 100ul
- 500ul
| Alias | SARS-CoV-2 RBD antibody, 2019-nCoV, Coronavirus |
| Catalog Number | MAV101 |
| Product Description | The product is specific for SARS-CoV-2 Spike Protein S1 subunit (Cat.#: COV362)and its RBD domain (Cat.#: COV363), and can inhibit the interaction between SARS-CoV-2 Spike Protein RBD and ACE2. Cat#. MAV101 and Cat#.MAV102 are antibody pair which is verified for ELISA. |
| Molecular Name | COVID-19 |
| Species | COVID-19 |
| Host | Human |
| Size | 100ul, 500ul |
| Clonity | Recombinant mAb |
| Clone Number | 1G6 |
| Concentration | 1mg/ml |
| Antibody Isotype | IgG1 |
| Formulation | 0.01M PBS, pH 7.4 |
| Background | 一种新型严重急性呼吸综合征(SARS)样冠状病毒(SARS-CoV-2)新近出现并在人类中快速传播,引发COVID-19。应对这一大流行疫情的关键在于理解病毒的受体识别机制,该机制调控其感染性、致病性和宿主范围。SARS-CoV-2和SARS-CoV在人类中识别相同的受体——血管紧张素转换酶2(ACE2)。研究人员解析了SARS-CoV-2刺突蛋白受体结合域(RBD)(经工程化改造以利于结晶)与ACE2复合物的晶体结构。与SARS-CoV RBD相比,SARS-CoV-2 RBD中一个ACE2结合脊具有更紧凑的构象;此外,SARS-CoV-2 RBD中的几个残基变化稳定了RBD-ACE2界面上的两个病毒结合热点。SARS-CoV-2 RBD的这些结构特征增强了其与ACE2的结合亲和力。此外,我们的研究显示,与SARS-CoV-2亲缘关系密切的蝙蝠冠状病毒RaTG13也同样利用人ACE2作为其受体。 |
| Immunogen | Native virus |
| Application | ELISA, POCT, Neu, Standard |
| Biological Activity | IC50 = 2.8 ng/mL using SARS-CoV-2 Inhibitor screening Kit |
| Cross-reactivity | React with SARS-CoV-2(COVID-19) S1-RBD protein. Do not react with other SARS-CoV-2 subunits. |
| Storage Condition | 本产品可在2℃-8℃下储存一个月。抗体产品在-20℃至-80℃下储存时,自收到之日起十二个月内稳定。避免反复冻融循环。 |
| Product Declaration | 本产品仅供研究使用,不得直接用于人体或注射。 |
0